MXPA97001839A - Process to establish gelat products - Google Patents
Process to establish gelat productsInfo
- Publication number
- MXPA97001839A MXPA97001839A MXPA/A/1997/001839A MX9701839A MXPA97001839A MX PA97001839 A MXPA97001839 A MX PA97001839A MX 9701839 A MX9701839 A MX 9701839A MX PA97001839 A MXPA97001839 A MX PA97001839A
- Authority
- MX
- Mexico
- Prior art keywords
- sulfate
- chloride
- ammonium
- gelatin
- iron
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 229920000159 gelatin Polymers 0.000 claims abstract description 73
- 235000019322 gelatine Nutrition 0.000 claims abstract description 73
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 68
- 108010010803 Gelatin Proteins 0.000 claims abstract description 61
- 239000008273 gelatin Substances 0.000 claims abstract description 61
- 239000000654 additive Substances 0.000 claims abstract description 35
- 230000000996 additive Effects 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 239000000047 product Substances 0.000 claims abstract description 18
- 238000003860 storage Methods 0.000 claims abstract description 18
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 16
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims abstract description 12
- 229960002989 Glutamic Acid Drugs 0.000 claims abstract description 12
- 239000004220 glutamic acid Substances 0.000 claims abstract description 12
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 12
- -1 nitrilotrismethylene phosphonic acid Chemical compound 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 239000001828 Gelatine Substances 0.000 claims abstract description 5
- 239000012467 final product Substances 0.000 claims abstract description 3
- 150000001299 aldehydes Chemical class 0.000 claims abstract 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 20
- 239000002775 capsule Substances 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 12
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 12
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Chemical compound [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 claims description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000004202 carbamide Substances 0.000 claims description 10
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 9
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 9
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 9
- BIGPRXCJEDHCLP-UHFFFAOYSA-N Ammonium bisulfate Chemical compound [NH4+].OS([O-])(=O)=O BIGPRXCJEDHCLP-UHFFFAOYSA-N 0.000 claims description 7
- LFVGISIMTYGQHF-UHFFFAOYSA-N Ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 7
- 229960005261 Aspartic Acid Drugs 0.000 claims description 7
- NMCUIPGRVMDVDB-UHFFFAOYSA-L Iron(II) chloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- 235000003704 aspartic acid Nutrition 0.000 claims description 7
- SOIFLUNRINLCBN-UHFFFAOYSA-N Ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 claims description 6
- 229960001230 Asparagine Drugs 0.000 claims description 6
- BAUYGSIQEAFULO-UHFFFAOYSA-L Iron(II) sulfate Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- GLFNIEUTAYBVOC-UHFFFAOYSA-L MANGANESE CHLORIDE Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 6
- OTYBMLCTZGSZBG-UHFFFAOYSA-L Potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- 235000009582 asparagine Nutrition 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 claims description 6
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 6
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 6
- 229940087748 lithium sulfate Drugs 0.000 claims description 6
- 235000018977 lysine Nutrition 0.000 claims description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 6
- 239000011565 manganese chloride Substances 0.000 claims description 6
- 235000002867 manganese chloride Nutrition 0.000 claims description 6
- 235000019837 monoammonium phosphate Nutrition 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 6
- 235000011151 potassium sulphates Nutrition 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 6
- 235000011152 sodium sulphate Nutrition 0.000 claims description 6
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims description 5
- 239000004254 Ammonium phosphate Substances 0.000 claims description 5
- RUTXIHLAWFEWGM-UHFFFAOYSA-H Iron(III) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 235000012538 ammonium bicarbonate Nutrition 0.000 claims description 5
- 239000001099 ammonium carbonate Substances 0.000 claims description 5
- 229910000148 ammonium phosphate Inorganic materials 0.000 claims description 5
- 235000019289 ammonium phosphates Nutrition 0.000 claims description 5
- ATRRKUHOCOJYRX-UHFFFAOYSA-N azanium;hydron;carbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 5
- 229910000360 iron(III) sulfate Inorganic materials 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 5
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 5
- 229960004198 Guanidine Drugs 0.000 claims description 4
- 229960004799 Tryptophan Drugs 0.000 claims description 4
- 229940045136 Urea Drugs 0.000 claims description 4
- 229960003121 arginine Drugs 0.000 claims description 4
- 229960000539 carbamide Drugs 0.000 claims description 4
- 229960004106 citric acid Drugs 0.000 claims description 4
- 229960003646 lysine Drugs 0.000 claims description 4
- 229940099596 manganese sulfate Drugs 0.000 claims description 3
- 239000011702 manganese sulphate Substances 0.000 claims description 3
- 235000007079 manganese sulphate Nutrition 0.000 claims description 3
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 claims description 3
- 229940099607 manganese chloride Drugs 0.000 claims description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K Iron(III) chloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims 10
- SQQMAOCOWKFBNP-UHFFFAOYSA-L Manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims 3
- 239000007903 gelatin capsule Substances 0.000 claims 3
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 claims 3
- YDONNITUKPKTIG-UHFFFAOYSA-N ATMP Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CP(O)(O)=O YDONNITUKPKTIG-UHFFFAOYSA-N 0.000 claims 1
- PEVUNNVMSNWMJO-UHFFFAOYSA-N C([O-])(O)=O.[NH4+].P(=O)([O-])([O-])[O-].[NH4+].[NH4+].[NH4+] Chemical compound C([O-])(O)=O.[NH4+].P(=O)([O-])([O-])[O-].[NH4+].[NH4+].[NH4+] PEVUNNVMSNWMJO-UHFFFAOYSA-N 0.000 claims 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-L iron;sulfate Chemical compound [Fe].[O-]S([O-])(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-L 0.000 claims 1
- 238000004090 dissolution Methods 0.000 description 34
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical class O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 29
- 235000019256 formaldehyde Nutrition 0.000 description 16
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229940022659 Acetaminophen Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000000988 Bone and Bones Anatomy 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- ZVAYUUUQOCPZCZ-UHFFFAOYSA-N 4-(diethoxyphosphorylmethyl)aniline Chemical compound CCOP(=O)(OCC)CC1=CC=C(N)C=C1 ZVAYUUUQOCPZCZ-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 235000015450 Tilia cordata Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 238000005020 pharmaceutical industry Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 108010013480 succinylated gelatin Proteins 0.000 description 1
- 229940007079 succinylated gelatin Drugs 0.000 description 1
Abstract
The present invention relates to a process for the manufacture of gelatin products with improved stability that withstand hot and humid storage conditions and / or aldehydes characterized in that at least one additive, preferably glutamic acid, tryptophan or nitrilotrismethylene phosphonic acid or a mixture thereof is It is incorporated into the gelatine before forming the final product in a common way, as well as the gelatin compositions used and the products obtained by the process.
Description
PROCESS FOR STABILIZING GELATIN PRODUCTS FIELD OF THE INVENTION This invention relates to a process for improving the stability of gelatin products against higher storage temperatures, transfections influenced with moisture and / or chemically, as well as appropriate gelatin compositions and its use in the manufacture of capsules or as coating agents or bonding tablets, coating materials.
DESCRIPTION OF THE PREVIOUS TECHNIQUE Gelatin is widely used in the pharmaceutical industry as well as in the market of healthy food supplements for manufacturing capsules as containers or as coating agents for capsules or other dosage forms or as adjuvants or excipients in pharmaceutical preparations as tablets A first objective of these dosage forms is to have a good disintegration after having been administered to allow a rapid dissolution of the active substances in the appropriate digestive organ. Any delay of disintegration could consequently delay or even reduce the effect of the drug. Consequently, this disintegration characteristic has to remain unchanged through time when the finished products are stored before use. Extensive stability tests of the solution have been carried out to assess this stability.
Unfortunately, as has been widely described in the literature, the risk of the gelatin product exhibiting a delay in disintegration over time is high. A major cause of the problem, exposure to certain aldehydes contained in the contents of the capsules in the initial stage or that originate from the decomposition of the drug or one of the excipients over time, have been reported in many references as a cause . The mechanism of this chemical interaction named "transenlace" has been well understood as the action of the aldehyde on the free amino groups of amino acids and especially lysine and arginine (G. Digenis et al., For publication in J. of Pharm Sci.). It has also been used in the sense that the gelatin overtranslink would render it totally insoluble and inappropriate for an enteric dosage form (G. Gutiérrez, FR-8201127).
Several patents have been published dealing with this issue. The resistance to the transenlace by formaldehydes can be obtained by chemically modifying the gelatin
(Succinylated gelatin: Toyo Jozo Co., JP 61/1863158 Nippon Elanco Co., JP-61/186314), by adding ions therein (Sanofi, FR-8708828) or silicones (RP Scherer, FR-2346/69) or peptides (NITTA, EP-0 335 982).
Another method for protecting the gelatin from the trans-links includes in the formula of the drug a formaldehyde receptor for dead cells (Tei oku Hormone Mfg. Co., JP-168874/1989 and Lion Corporation EP-0 242 855).
Some references in the literature have also reported that exposure or storage to / in hot and humid conditions is another reason for the delay in the disintegration of gelatin products. These conditions were reported in the range of 25 to 55 ° C and a humidity range of 40% to 90% relative humidity. The above seems to be very important for most gelatine pharmaceutical applications where storage stability at 40 ° C with 75% relative humidity is required for 3 to 6 months without significant delay in the dissolution of the drug.
This phenomenon is described extensively in the literature, but no proposal has been made to explain the mechanism of the chemical reactions involved as responsible for the poorer dissolution performance of gelatin: H.W. Gouda et al., Intl. Jour. Pharmaceutics, 18, 1984, 213-215; S.A. Khalil et al., Pharmazie, 29 Hl, 1974, 36-37; T.C. Hahl et al., Drig Dvpt. Industr. Pharmacy, 17 (7), 1991, 1001-1016; M. Dey et al., Pharmaceutical Res., 10 (9), 1993, 1295-1300; K.S. Murphy et al., Pharm. Techno., March, 1989, 74-82. In the state of the art, no method is known to increase the resistance of gelatin to storage under hot and humid conditions as described above.
SUMMARY OF THE INVENTION The present invention relates to a process for the manufacture of gelatin products having an improved stability against storage under hot and humid conditions and / or aldehydes to improve the dissolution of the gelatin products comprising the incoforation of Additives in the gelatin solution and form the final product as always. Another aspect of the invention are the gelatin compositions used for the gelatin products prepared by the process.
DETAILED DESCRIPTION OF THE PREDILECT EXAMPLES The gelatin to be used with the present invention may be of pork skin processed with acids known as gelatins A, of bones processed with lime known as gelatins B, of calf skin known as gelatins C, bones processed with acid known as AB gelatins or a combination of two or more of these gelatins.
The additives are selected from the group consisting of ammonium sulfate, ammonium hydrogen sulfate, ammonium hydrogencarbonate, ammonium phosphate, ammonium hydrogen phosphate, ammonium dihydrogenphosphate, ammonium thiocyanate, sodium sulfate, sodium chloride, potassium sulfate, potassium chloride, lithium sulfate, lithium chloride, calcium sulfate, calcium chloride, magnesium sulfate, magnesium chloride, iron (II) sulfate, iron (II) chloride, iron (III) sulfate, chloride iron (III), manganese sulfate (II), manganese chloride (II), glutamic acid, aspartic acid, asparagine, lysine, tryptophan, arginine, guanidine, urea, citric acid, ascorbic acid, ethylenediamine tetraacetate, nitrilotrismetilene acid phosphonic
The amount of additives is up to 25%, preferably 0.1 to 10% by weight of the dry gelatin. Each additive can be added alone or in combination with one or more additives.
Two types of storage conditions were studied: 1) Hot and humid conditions: the temperature varied between 20 and 55 ° C and the humidity between 40% and 90% relative humidity.
2) Formaldehyde: a) Capsules were filled with lactose contaminated with formaldehyde at levels ranging from 0-200 ppm, preferably between 1 and 60 ppm. These capsules were stored in closed bottles at 50 ° C for up to 2 months or in open air in hot and humid conditions for up to 6 months. b) Lactose powder films contaminated with formaldehyde were stored at levels between 0 and 200 ppm, preferably between 1 and 50 ppm. The films were placed in the contaminated lactose powder in a closed plastic box and kept at 50 ° C for 1 month.
Dissolution Measures: Dissolution measurements were made with the apparatus described in USP XXII, method II (paddle at 50 rpm). The medium was demineralized water at 37 ° C ± 0.5 ° C and two procedures were used, one for the capsules and the other for the gelatin films. The samples were added in the middle with a special lead that prevents them from floating.
1. Capsule Dissolution: The capsules were previously stored under one or both of the storage conditions described above. The capsules were filled with Acetaminophen and dissolved in water at 37 ° C under agitation (paddle at 50 rpm). The percentage of dissolved Acetaminophen was determined by UV spectrophotometry at 300 nm. The required level of dissolved Acetaminophen is greater than 80% in 45 minutes.
2. Dissolution of Gelatin Film Gelatin films are melted on glass platforms. These films are stored in one or both of the storage conditions described above. Demineralized water is then added to the films at 37 ° C under agitation (paddle at 50 rpm) and the percentage of dissolution is determined by UV spectrophotometry at 217 nm. Films without translinks have a solution of more than 90% in 6 minutes.
The following examples will demonstrate how the addition of the inventive compounds increases the resistance of the gelatins to the transenlace by hot and humid storage and / or formaldehydes.
Example 1: We studied the effect of the addition of ammonium sulfate (2% by weight of gelatin) on the resistance of gelatin to the formaldehyde transenlace. The type of gelatin A 240 and type B 200 or two different suppliers with two groups each were studied. The gelatin films were melted from a 30% gelatin solution containing 2% by weight of ammonium sulfate ((NH4) 2S04) and without additives (Reference). The films were dried under ambient conditions for 24 hours and solution samples were prepared and stored in lactose powder contaminated with formaldehyde (at 5 ppm formaldehyde at 50 ° C for 1 week).
The dissolution results (%) are summarized in Table 1 in comparison to the average values of 4 groups stored for 1 week under ambient conditions.
TABLE 1
Gelatine Supply Group Reference (NH4) 2S04 3 min. 6 min 3 min. 6 min A 1 10% 35% 80% 96% 2 7% 46% 86% 98%
A 240 B 1 11% 60% 76% 98% 2 20% 70% 60% 96% Average value for 4 groups 81% 97% 74% 93%
Table 1 demonstrates a very impressive resistance to the transenlace of
formaldehyde. Gelatin films with ammonium sulfate have virtually
same dissolution results in 3 and 6 minutes as the gelatin films stored
in ambient conditions (average values for 4 groups). A dramatic decrease in the
dissolution was noted for the films without any additive (Reference), especially for
dissolution measures in 3 minutes.
Example 2:
The effect of the addition of nitrilotrismethylene phosphonic acid (AMP, Maquol P320) in
the dissolution of gelatin films stored in the presence of formaldehyde is
study The films were prepared by melting a gelatin solution (30%
by weight of water) with Masquol P320 content (1% by weight of gelatin on
Glass platform and drying in ambient conditions for 24 hours.
The dissolution samples were then prepared and stored sunk in
lactose contaminated with formaldehyde in a closed plastic box for 1 week at 50 ° C before dissolution measures.
The dissolution results are illustrated in the following Table 2.
TABLE 2 Gelatine U P Dissolution 3 min. 6 min 9 min 12 min 15 min
A 240 0% 0% 3% 10% 16% 21% 1% 3% 15% 26% 41% 52% B 200 0% 8% 42% 70% 84% 87% 1% 8% 77% 89% 93% 94%
Here the beneficial effect of the addition of an additive, Maquol P320, on the resistance of gelatin films to the formaldehyde transenlace is clearly demonstrated.
Indeed, a significant increase in the dissolution of gelatin films was observed in both films A 240 (+ 150% in 15 minutes) and B 200 films (+ 85% in 6 minutes).
Example 3:
The gelatin films with acidic ammonia as additives were prepared and stored under hot and humid conditions before the dissolution measures. The
gelatin films were melted from 30% solution by weight with content of already
be 1% tryptophan or 1% glutamic acid. Gelatin films of A 240 and B
200 were prepared. The films were dried under ambient conditions for 24 hours before sample preparation. The samples were stored at 50 ° C and 80% relative humidity for 3 (A240) or 4 (B200) months before the dissolution measures. The
results are illustrated in Table 3 in comparison to gelatin without additives registered at room temperature (Reí).
TABLE 3
Latin Additive Dissolution (%) after minutes 3 6 9 12 15
240 0% 6 8 14 36 67 1% Glu 6 50 92 99 100 1% Tf 10 87 97 99 100
200 0% 3 76 92 98 98 1% Glu 54 92 97 99 100 1% Tf 59 97 100 100 100
240 0% Ref 72 96 99 100 100
200 0% Ref. 96 100 100 100 100
The dissolution results, compared to the reference tests,
show that the addition of amino acids, specifically glutamic acid and tryptophan to
level of 1% (with respect to dry gelatin) increases the dissolution of films of
gelatin especially in minutes 3 for B 200 and minute 9 for gelatins A 240.
In both cases, we reach the total dissolution of gelatin films (dissolution
100%) more quickly with additives than the reference films studied under the
same conditions.
Example 4:
Gelatin films were prepared with salts of organic compounds as in
Example 3. The following products were added at the level of 1% compared to the weight of
gelatin: urea and Masquol P320 (AMP).
The dissolution measurements were carried out as in Example 3 and the results are summarized in the following Table 4:
TABLE 4
Jelatina Additive Dissolution (%) after minutes 3 6 9 12 15
A 240 0% 6 8 14 36 67 1% Glu 10 92 99 100 100 1% Amp 94 97 100 100 100
B 200 0% 3 76 92 98 98 1% Glu 79 97 99 100 100 1% Amp 77 94 99 100 100
A 240 0% Ref. 72 96 99 100 100
B 200 0% Ref. 96 100 100 100 100
The added organic compounds (Urea, Maquol P320) significantly increased the dissolution of gelatin films of both types A 240 and B200.
For A 240 the 100% solution is obtained around 6 minutes compared to a solution of only 8% for gelatin films without additives. This result is comparable to reference films (Ref.) Stored under normal conditions. The solution is greater than 75% for gelatin B 200 after only 3 minutes (3% for B 200 films without additives). These results are comparable to reference films B 200 (Ref.) Stored under normal conditions.
As demonstrated from these examples, the incoforation of select additives in the gelatin films increases the resistance of the gelatin films and capsules to the link in the presence of aldehydes or when stored in hot and humid conditions.
Example 5:
The dissolution of capsules containing additives and are filled with lactose with
Formaldehyde content (5 ppm or 20 ppm) and stored at 50 ° C in closed bottles for 1 or 2 months was studied. The results are expressed as the level of dissolution of
acetaminophen contained within the capsules and was measured according to method 2 USP XXII.
TABLE 5
Test Additive Dissolution (%) after minutes 15 30 45 60 75 0% 12 40 57 71 79 2% (I) 39 68 87 95 97
B 00 %% 2244 50 66 78 88 2% (I) 40 72 90 98 100 1% (II) 39 79 95 100 100 0% 43 79 94 98 99
Test A: Storage for 4 weeks at 50 ° C, 20ppm formaldehyde.
Test B: Storage for 2 months at 50 ° C, 5 ppm formaldehyde.
Test C: Reference storage under ambient conditions.
Additive (I): Ammonia sulphate.
Additive (II): Aspartic acid.
The dissolution of capsules with content of additives is better than the reference.
This solution is equal to the dissolution of standard capsules stored under conditions
ambient. While what is currently considered as the specimens have been described
of the invention, those with experience in the art will realize that
Several changes and modifications can be made to the invention without leaving the spirit of the
invention and it is intended to claim all those changes and modifications as within the
scope of the invention.
Claims (11)
- CLAIMS 1. A process for the manufacture of gelatin products with improved stability for storage under hot and humid conditions and / or aldehydes characterized in that at least one additive selected from the group consisting essentially of ammonium sulfate, ammonium hydrogen sulfate, hydrogen carbonate ammonium phosphate, ammonium phosphate, ammonium hydrogen phosphate, ammonium dihydrogen phosphate, ammonium thiocyanate, sodium sulfate, sodium chloride, potassium sulfate, potassium chloride, lithium sulfate, lithium chloride, calcium sulfate, calcium chloride , magnesium sulfate, magnesium chloride, iron (II) sulfate, iron (II) chloride, iron (III) sulfate, iron (III) chloride, manganese (II) sulfate, manganese (II) chloride , glutamic acid, aspartic acid, asparagine, Usina, tryptophan, arginine, guanidine, urea, citric acid, ascorbic acid, ethylenediamine tetraacetate, nitrilotrismethylene phosphonic acid.
- 2. A process according to Claim 1 wherein the additive or mixture of additives is uncolored in the gelatin in an amount of up to 25%.
- 3. A process according to Claim 2, wherein the additive or admixture of additives is uncolored in the gelatin in an amount of from about 0.1% to about 10% by weight of the dry gelatin.
- 4. A process according to Claim 3 for the process of films, capsules, containers or gelatin covers.
- 5. A gelatin composition containing additives with improved stability for storage under hot and humid conditions and / or aldehydes, comprising at least one additive selected from the group consisting essentially of ammonium sulfate, ammonium hydrogen sulfate, ammonium hydrogen carbonate, phosphate ammonia, ammonium hydrogen phosphate, ammonium dihydrogen phosphate, ammonium thiocyanate, sodium sulfate, sodium chloride, potassium sulfate, potassium chloride, lithium sulfate, lithium chloride, calcium sulfate, calcium chloride, magnesium sulfate, magnesium chloride, iron (II) sulfate, iron (II) chloride, iron (III) sulfate, iron (III) chloride, manganese (II) sulfate, manganese (II) chloride, glutamic acid, acid aspartic acid, asparagine, lysine, tryptophan, arginine, guanidine, urea, citric acid, ascorbic acid, ethylenediamine tetraacetate, nitrilotrismethylene phosphonic acid or mixtures thereof.
- 6. A gelatin product prepared from compositions with improved stability for storage under hot and humid conditions and / or aldehydes comprising at least one additive selected from the group consisting essentially of ammonium sulfate, ammonium hydrogen sulfate, ammonium hydrogencarbonate, ammonium phosphate, ammonium hydrogen phosphate, ammonium dihydrogen phosphate, ammonium thiocyanate, sodium sulfate, sodium chloride, potassium sulfate, potassium chloride, lithium sulfate, lithium chloride, calcium sulfate, calcium chloride, sulfate magnesium, magnesium chloride, iron (II) sulfate, iron (II) chloride, iron (III) sulfate, iron (III) chloride, manganese (II) sulfate, manganese (II) chloride, glutamic acid , aspartic acid, asparagine, lysine, tryptophan, arginine, guanidine, urea, citric acid, ascorbic acid, ethylenediamine tetraacetate, nitrilotrismethylene phosphonic acid or a mixture thereof.
- 7. A gelatin product according to Claim 6, wherein said gelatin product comprises a film, capsule, container or gelatin shell.
- 8. A gelatin product according to Claim 6, wherein said film, capsule, container or gelatin shell comprises 0.1 to 10% by weight of at least one additive from the group consisting of urea, tryptophan, glutamic acid or nitrilotrimethylene phosphonic acid or mixtures thereof.
- 9. A pharmaceutical gelatin capsule shell prepared from compositions with improved stability for storage under hot and humid conditions and / or aldehydes comprising at least one additive selected from the group consisting essentially of ammonium sulfate, ammonium hydrogen sulfate, ammonium hydrogencarbonate, ammonium phosphate, ammonium hydrogen phosphate, ammonium dihydrogen phosphate, ammonium thiocyanate, sodium sulfate, sodium chloride, potassium sulfate, potassium chloride, lithium sulfate, lithium chloride , calcium sulfate, calcium chloride, magnesium sulfate, magnesium chloride, iron (II) sulfate, iron (II) chloride, iron (III) sulfate, iron (III) chloride, manganese sulfate (II) ), manganese (II) chloride, glutamic acid, aspartic acid, asparagine, lysine, tryptophan, arginine, guanidine, urea, citric acid, ascorbic acid, ethylenediamine tetraacetate, nitrilotrismethylene phosphonic acid or a mixture thereof.
- 10. A shell of pharmaceutical gelatin capsule containing from 0.1 to 10% by weight of at least one additive from the group consisting essentially of ammonium sulfate, ammonium hydrogen sulfate, ammonium hydrogencarbonate, ammonium phosphate, ammonium hydrogen phosphate, ammonium dihydrogen phosphate, ammonium thiocyanate, sodium sulfate, chloride sodium, potassium sulfate, potassium chloride, lithium sulfate, lithium chloride, calcium sulfate, calcium chloride, magnesium sulfate, magnesium chloride, iron (II) sulfate, iron (II) chloride, sulfate iron (III), iron (III) chloride, manganese sulfate (II), manganese chloride (II), glutamic acid, aspartic acid, asparagine, lysine, tryptophan, arginine, guanidine, urea, citric acid, ascorbic acid , ethylenediamine tetraacetate, nitrilotrismethylene phosphonic acid or mixtures thereof.
- 11. A pharmaceutical gelatin capsule shell according to claim 10 containing from 0.1 to 10% by weight of at least one additive from the group consisting essentially of urea, tryptophan, glutamic acid or nitrilotrismethylene phosphonic acid or mixtures thereof. ABSTRACT OF THE INVENTION Process for the manufacture of gelatin products with improved stability against under hot and humid storage conditions and / or aldehydes characterized in that at least one additive, preferably glutamic acid, tryptophan or nitrilotrismethylene acid and / or a mixture of these it is incubated in the gelatine before forming the final product as always as well as the gelatin compositions used and the products obtained by the process.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08334974 | 1994-11-07 | ||
US08/334,974 US5620704A (en) | 1994-11-07 | 1994-11-07 | Process for stabilizing gelatin products |
PCT/US1995/013950 WO1996014365A2 (en) | 1994-11-07 | 1995-10-31 | Process for stabilizing gelatin products |
Publications (2)
Publication Number | Publication Date |
---|---|
MXPA97001839A true MXPA97001839A (en) | 1997-06-01 |
MX9701839A MX9701839A (en) | 1997-06-28 |
Family
ID=23309685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9701839A MX9701839A (en) | 1994-11-07 | 1995-10-31 | Process for stabilizing gelatin products. |
Country Status (12)
Country | Link |
---|---|
US (1) | US5620704A (en) |
EP (1) | EP0791037B1 (en) |
JP (1) | JP4100704B2 (en) |
KR (1) | KR100402038B1 (en) |
CN (1) | CN1177903C (en) |
AT (1) | ATE263817T1 (en) |
DE (1) | DE69532858T2 (en) |
DK (1) | DK0791037T3 (en) |
ES (1) | ES2215179T3 (en) |
MX (1) | MX9701839A (en) |
PT (1) | PT791037E (en) |
WO (1) | WO1996014365A2 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997033568A1 (en) * | 1996-03-12 | 1997-09-18 | Novartis Ag | Filled gelatin capsules having a reduced degree of cross-linking |
US5965839A (en) * | 1996-11-18 | 1999-10-12 | Jaycor | Non-lethal projectile for delivering an inhibiting substance to a living target |
US6393992B1 (en) * | 1996-11-18 | 2002-05-28 | Jaycor Tactical Systems, Inc. | Non-lethal projectile for delivering an inhibiting substance to a living target |
US20050188886A1 (en) * | 1996-11-18 | 2005-09-01 | Pepperball Technologies, Inc. | Non-lethal projectile systems |
US7194960B2 (en) * | 1996-11-18 | 2007-03-27 | Pepperball Technologies, Inc. | Non-lethal projectiles for delivering an inhibiting substance to a living target |
US20030047105A1 (en) * | 1996-11-18 | 2003-03-13 | Jaycor Tactical Systems, Inc. | Non-lethal projectile systems |
US6543365B1 (en) | 1996-11-18 | 2003-04-08 | Jaycor Tactical Systems, Inc. | Non-lethal projectile systems |
GB9911129D0 (en) * | 1999-05-14 | 1999-07-14 | Rafati Hasan Dr | Enteric coating formulations in a powder form for dissolution in water |
US20050156340A1 (en) | 2004-01-20 | 2005-07-21 | E Ink Corporation | Preparation of capsules |
GB2385058A (en) * | 2002-02-08 | 2003-08-13 | Nemit Ltd | Toiletry products |
AU2003240536B2 (en) * | 2002-06-05 | 2007-11-15 | Ivax Pharmaceuticals, S.R.O. | Reduction of gelatin cross-linking |
EP1526846A2 (en) * | 2002-07-31 | 2005-05-04 | Pharmacia Corporation | Gelatin capsule exhibiting reduced cross-linking |
JP2004075582A (en) * | 2002-08-13 | 2004-03-11 | Takeda Chem Ind Ltd | Method for stabilizing ingredient other than active ingredient prescribed in solid pharmaceutical composition |
JPWO2004037293A1 (en) * | 2002-10-22 | 2006-02-23 | 大日本住友製薬株式会社 | Stabilizing composition |
US7526998B2 (en) * | 2003-02-10 | 2009-05-05 | Pepperball Technologies, Inc. | Stabilized non-lethal projectile systems |
EP1498117A1 (en) * | 2003-07-15 | 2005-01-19 | Pfizer GmbH Arzneimittelwerk Gödecke | A pharmaceutical gelatin-capsule or gelatin containing capsule preparation showing an improved stability, a process for making the capsules and a process for improving the stability of gelatin-capsules |
JP4457641B2 (en) * | 2003-11-10 | 2010-04-28 | 味の素株式会社 | Gelatin capsule |
US9267167B2 (en) | 2004-06-28 | 2016-02-23 | Becton, Dickinson And Company | Dissolvable films and methods including the same |
US20070048366A1 (en) * | 2005-08-26 | 2007-03-01 | Jen-Chi Chen | Gelatin-based coatings having improved durability |
US20080134927A1 (en) * | 2006-10-05 | 2008-06-12 | Skellern Michael J | Projectile with dispersible contents and method of manufacturing the same |
PE20081482A1 (en) * | 2006-12-20 | 2008-12-23 | Novartis Ag | GELATINE CAPSULES CONTAINING AN ACID |
CN101220090B (en) * | 2007-01-09 | 2010-10-13 | 上海百瑞吉生物医药有限公司 | Multi-modification derivant of glutin and crosslinked material thereof |
JP2011136927A (en) | 2009-12-28 | 2011-07-14 | Pfizer Inc | Gelatin capsule and gelatin composition for forming capsule coating film |
CN102965030B (en) * | 2012-11-05 | 2014-05-14 | 南昌大学 | Preparation method of high-gel-strength fish scale gelatin |
CN103487739A (en) * | 2013-09-27 | 2014-01-01 | 昆山迈致治具科技有限公司 | PCB performance detection jig with heat dissipation function and impurity removal function |
KR101460784B1 (en) * | 2013-10-08 | 2014-11-17 | 한국과학기술연구원 | Composition of preservatives for wooden structural assets having high flame retardant |
CN103951832B (en) * | 2014-04-30 | 2015-08-26 | 湖南尔康北山明胶有限公司 | A kind of gelatin-L-glutamic acid cross-linked composite and preparation technology thereof |
EP3200614B1 (en) * | 2014-09-30 | 2018-03-07 | Unilever NV | Food concentrate |
WO2017131001A1 (en) * | 2016-01-25 | 2017-08-03 | サントリーホールディングス株式会社 | Composition including ellagic acid gelatin capsule |
CN106433149B (en) * | 2016-08-18 | 2019-02-22 | 宁波大学 | It is a kind of to be sliced fresh-keeping edible composite film and preparation method thereof for dry-cured ham |
JP6960862B2 (en) * | 2018-01-15 | 2021-11-05 | 日本バイリーン株式会社 | A spinning solution composed of a gelatin solution and the gelatin solution, a method for producing a fiber aggregate using the spinning solution, and a method for producing a film and a composite using the gelatin solution. |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE225426C (en) * | ||||
US2467715A (en) * | 1946-03-08 | 1949-04-19 | Nat Starch Products Inc | Manufacture of animal glue jellies |
SU563156A1 (en) * | 1975-12-08 | 1977-06-30 | Всесоюзный научно-исследовательский институт консервной и овощесушильной промышленности | Method of canning tomato products in containers |
JPS5391118A (en) * | 1977-01-20 | 1978-08-10 | Honma Kenkyusho | Production of antigen for complement binding reaction by freeze drying |
JPS6023859B2 (en) * | 1978-11-14 | 1985-06-10 | 神崎製紙株式会社 | Method for manufacturing microcapsules |
DE3008658A1 (en) * | 1979-03-09 | 1980-09-11 | Fuji Photo Film Co Ltd | METHOD FOR PRODUCING MICROCAPSULES |
US4333849A (en) * | 1980-06-02 | 1982-06-08 | The Mead Corporation | Encapsulation process |
JPS5939834A (en) * | 1982-08-31 | 1984-03-05 | Morishita Jintan Kk | Film composition for pharmaceutical |
DD225426A1 (en) * | 1984-06-22 | 1985-07-31 | Jenapharm Veb | PROCESS FOR PRODUCING STABLE GELANTINE PREPARATIONS |
FR2617047B1 (en) * | 1987-06-23 | 1991-05-10 | Sanofi Sa | TANNING RESISTANT GELATIN COMPOSITION, CAPSULES BASED ON THIS COMPOSITION AND THEIR PHARMACEUTICAL APPLICATION, IN PARTICULAR TO FENOFIBRATE |
US5376381A (en) * | 1988-02-25 | 1994-12-27 | The Liposome Company, Inc. | Integrity protected gelatin |
ES2151940T3 (en) * | 1994-08-05 | 2001-01-16 | Shionogi & Co | HARD GELATIN CAPSULES RESISTANT TO DENATURALIZATION AND PROCEDURE FOR PREPARATION. |
-
1994
- 1994-11-07 US US08/334,974 patent/US5620704A/en not_active Expired - Lifetime
-
1995
- 1995-10-31 DK DK95939627T patent/DK0791037T3/en active
- 1995-10-31 CN CNB951960822A patent/CN1177903C/en not_active Expired - Fee Related
- 1995-10-31 AT AT95939627T patent/ATE263817T1/en not_active IP Right Cessation
- 1995-10-31 PT PT95939627T patent/PT791037E/en unknown
- 1995-10-31 JP JP51536896A patent/JP4100704B2/en not_active Expired - Lifetime
- 1995-10-31 MX MX9701839A patent/MX9701839A/en not_active IP Right Cessation
- 1995-10-31 ES ES95939627T patent/ES2215179T3/en not_active Expired - Lifetime
- 1995-10-31 KR KR1019970702997A patent/KR100402038B1/en not_active IP Right Cessation
- 1995-10-31 DE DE69532858T patent/DE69532858T2/en not_active Expired - Lifetime
- 1995-10-31 EP EP95939627A patent/EP0791037B1/en not_active Expired - Lifetime
- 1995-10-31 WO PCT/US1995/013950 patent/WO1996014365A2/en active IP Right Grant
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA97001839A (en) | Process to establish gelat products | |
US5620704A (en) | Process for stabilizing gelatin products | |
FI80592B (en) | FOERFARANDE FOER STABILISERING AV PHARMACEUTISKA PREPARAT, SOM AER I SUSPENSINOSFORM OCH INNEHAOLLER SUKRALFAT. | |
US4474749A (en) | Anticariogenetic chewing gum | |
US2956926A (en) | Coated citric acid particles | |
US4668665A (en) | Formulation of sucralfate | |
EP1062274A1 (en) | Polyvinyl alcohol compositions | |
IE48879B1 (en) | An analgesic effervescent powder and process for its preparation | |
US3653934A (en) | Composition for making gastro-resistant gelatin capsules | |
JPH03504968A (en) | Controlled release of active ingredients from capsules with salt-sensitive shell material | |
JP3530235B2 (en) | Hemodialysis agent | |
FR2617047A1 (en) | Gelatin composition which withstands tanning, capsules based on this composition and their pharmaceutical application, in particular to fenofibrate | |
JP4387192B2 (en) | Method for preparing tablets containing S-adenosylmethionine | |
JP3472317B2 (en) | Coated preparation | |
JP2809971B2 (en) | Hemodialysis preparation | |
CA2199155C (en) | Process for stabilizing gelatin products | |
JPH07550B2 (en) | Essential oil containing soft capsule | |
US4987031A (en) | Capsule | |
US3738952A (en) | Stabilized shellac sealing coating for tablets | |
KR100475974B1 (en) | Hard gelatine capsules denatured and preparation method thereof | |
US3239420A (en) | Gelatin composition | |
JPH0135630B2 (en) | ||
JPH0242811B2 (en) | ||
JP2003230363A (en) | Royal jelly preparation | |
JPH0380930A (en) | Composition of gelatin coating |